HOPE - HOPE

La cadena de opciones muestra datos clave de las opciones de acciones de Hope Bancorp a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Hope Bancorp..

Hope Bancorp (NASDAQ:HOPE) Bolsa, Cadena de Opciones

Hope Bancorp

Hope Bancorp Inc is a bank holding company engaged in providing financial services. It offers core business banking products for small and medium-sized businesses and individuals. Services offered by the bank include online banking, mobile banking, mortgage loans, credit cards, investment and wealth management services and other banking services.

Hope Bancorp Inc

<ul>
<li>Following last week's <a href="https://www.whitehouse.gov/presidential-actions/2025/04/unleashing-americas-offshore-critical-minerals-and-resources/">Executive Order</a>, ‘Unleashing America's Offshore Critical Minerals and Resources', TMC USA has submitted applications to the National Oceanic and Atmospheric Administration (NOAA) for two exploration licenses and one commercial recovery permit under the Deep Seabed Hard Mineral Resources Act (DSHMRA)</li>
<li>The commercial recovery permit application advances TMC's timeline ahead of its original June 27 application target, further strengthening the Company's leadership in the deep-sea minerals sector</li>
<li>The application area for the commercial recovery permit, TMC USA-A_2, covers a total combined area of 25,160 square kilometers in the Clarion Clipperton Zone which includes areas that contain the Company's already indicated and measured resources</li>
<li>TMC USA has also submitted two exploration license applications: TMC USA-A and TMC USA-B with a total combined area of 199,895 square kilometers</li>
<li>We believe the TMC USA-A and USA-B exploration areas contain SEC SK 1300-compliant resources of 1,635 million wet tonnes of polymetallic nodules, with an additional estimated 500 million tonnes of exploration upside. Together, the resource is estimated to contain approximately 15.5 million tonnes of nickel, 12.8 million tonnes of copper, 2.0 million tonnes of cobalt, and 345 million tonnes of manganese &nbsp;</li>
</ul>
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- TMC the metals company Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) (TMC or the Company), an explorer of the world's largest undeveloped resource of critical metals for infrastructure, defense, energy and future technologies, today announced that its U.S. subsidiary, The Metals Company USA LLC (TMC USA), has submitted applications for a commercial recovery permit and two exploration licenses under the Deep Seabed Hard Mineral Resources Act (DSHMRA) and National Oceanic and Atmospheric Administration (NOAA) implementing regulations which form the U.S. seabed mining code.

News

TMC USA Submits Application For Commercial Recovery Of Deep-Sea Minerals In High Seas Under U.S. Seabed Mining Code

Morgan Stanley analyst Craig Hettenbach maintains Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) with a Equal-Weight and lowers the price target from $60 to $40.

Price Target

Analyst Ratings

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Morgan Stanley Maintains Equal-Weight on Hims & Hers Health, Lowers Price Target to $40

– New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in people with primary biliary cholangitis (PBC) –
– Additional presentations will showcase the potential for maintained virologic response following treatment with investigational bulevirtide in people with hepatitis delta virus (HDV) –
– Presentations in hepatitis B virus (HBV) and hepatitis C virus (HCV) will underscore Gilead's commitment to advancing scientific research and our understanding of viral hepatitis in the real-world setting –

Biotech

Events

General

GILD

Gilead To Present New Research To EASL Congress

Franklin Financial Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRAF#NASDAQ">FRAF</a>) reported quarterly earnings of $0.88 per share. This is a 14.29 percent increase over earnings of $0.77 per share from the same period last year. The company reported $20.17 million in sales this quarter. This is a 13.68 percent increase over sales of $17.74 million the same period last year.

Earnings

FRAF

Franklin Financial Servs Q1 EPS $0.88 Up From $0.77 YoY, Sales $20.17M Up From $17.74M YoY

ASBP

Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval For In-Human Clinical Trial Protocol Of Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Outperform rating and announces Price Target of $5.

Initiation

PRQR

Evercore ISI Group Initiates Coverage On ProQR Therapeutics with Outperform Rating, Announces Price Target of $5

Tempus AI Announces Publication Of Its Study 'Analytical Validation of NGS-based Comprehensive Liquid Biopsy Assay for Therapy' In The Journal of Molecular Diagnostics

Health Catalyst's Improvement Expertise Built on Microsoft Azure and Azure AI Foundry to Drive Reliable Insight and Sustained Outcomes for Care Providers

HCAT

MSFT

Health Catalyst Partners With Microsoft To Accelerate AI Adoption And Transformation For Care Delivery Organizations

WIIM

PMAX

Powell Max shares are trading lower after the company reported FY24 financial results.

EDAP

EDAP TMS shares are trading higher after the company announced the FARP study achieved its primary endpoint.

Johns Hopkins Medicine's Valerie Lee, MD joins Michael J. Pishvaian, MD in an Appointed Key Role for TIGeR-PaC Trial
By becoming an additional clinical site for TIGeR-PaC, Johns Hopkins Medicine joins several esteemed cancer centers to support RenovoRx's initiative to complete patient enrollment for the trial during 2025
&nbsp;

RNXT

Johns Hopkins Medicine Initiates Enrollment For RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial

Canaccord Genuity analyst Kyle Mikson maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Hold and lowers the price target from $115 to $92.

ILMN

Canaccord Genuity Maintains Hold on Illumina, Lowers Price Target to $92

General Motors Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) recalled over 877,000 vehicles with the 6.2-liter V8 engine due to possible defects. The company has also issued a stop-sale order for the affected models.
What Happened: The U.S. National Highway Traffic Safety Administration (NHTSA) had launched a probe into the engine after the agency received multiple complaints of engine failure. While the investigation is still ongoing, GM has issued the recall, <a href="https://www.caranddriver.com/news/a64611938/chevy-silverado-tahoe-cadillac-escalade-defective-v8-recall/">reported</a> Car and Driver on Tuesday.
GM says the issue stems from defects in the engine's crankshaft and connecting rods. All engines will be inspected by the company and will be repaired or replaced should there be any defects.
The company says the affected models — all manufactured from 2021-2024 — include the Cadillac Escalade and Escalade ESV. Chevrolet models like the Silverado 1500, Chevrolet Suburban, and Chevrolet Tahoe are also recalled. The list also includes the GMC Sierra 1500, Yukon, as well as Yukon XL.
GM did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
Why It Matters: The news comes in during an uncertain time for GM, and the U.S. auto sector at large, amid the rising U.S.-China trade tensions. Experts have suggested that companies like GM could <a href="https://www.benzinga.com/25/04/44756759/new-research-shows-donald-trumps-25-tariffs-could-cost-auto-companies-108billion-report">stand to lose billions</a> of dollars due to the auto tariffs.
GM, along with Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), also faces the risk of getting a negative rating, according to a report published by ratings agency S&amp;P, due to the auto tariffs. However, Donald Trump's decision to <a href="https://www.benzinga.com/25/04/45059191/donald-trump-will-reduce-impact-on-us-auto-industry-by-alleviating-some-auto-tarrifs-report">alleviate some tariffs</a> could prove to be a boost for GM.&nbsp;&nbsp;
Elsewhere, GM also faces a <a href="https://www.benzinga.com/25/04/44917481/general-motors-faces-fresh-lawsuit-for-alleged-violation-of-customers-privacy-report">multi-district lawsuit </a>for allegedly violating its customers' privacy by collecting and selling data without consent, which the company denies.
Price Action: GM Stock currently trades for $47.24 on the NYSE, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.&nbsp;
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/44916042/general-motors-has-no-plans-to-move-ev-production-away-from-mexico-despite-tariff-uncertainty">General Motors Has No Plans To Move EV Production Away From Mexico Despite Tariff Uncertainty</a></li>
</ul>
Photo courtesy: Jonathan Weiss / Shutterstock.com

Markets

Tech

General Motors Recalls Nearly 900K Trucks, SUVs Over Engine Malfunction

Baird analyst Joe Vruwink maintains Roper Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) with a Outperform and raises the price target from $660 to $668.

Baird Maintains Outperform on Roper Technologies, Raises Price Target to $668

Contracts

LUNR

Texas Space Commission Selects Intuitive Machines For Up To $10M Grant From Space Exploration and Research Fund

As the U.S. and China continue to send mixed signals about the progress of their trade talks, economists at&nbsp;Morgan Stanley&nbsp;project that both nations will begin negotiations and slowly decrease&nbsp;tariffs on Chinese imports to&nbsp;60% by the end of Q2.
What Happened: Despite the anticipated discussions, tariffs are not expected to revert to their pre-January 25 levels. More in-depth talks in the second half of the year could further lower tariffs on Chinese imports to 34% by the end of 2025, indicating the abolition of the 20% fentanyl-related tariff.
"We believe that both the US and China will want a comprehensive deal, but that given the multiple issues involved, the discussions are likely to be complex and will take time to complete," stated Morgan Stanley, <a href="https://www.scmp.com/economy/global-economy/article/3308345/us-china-seen-reducing-tariffs-year-much-damage-already-done-analysts-say?module=top_story&amp;pgtype=homepage">reported</a> The SCMP.
Due to the ongoing disruption in the economic cycle, Morgan Stanley anticipates that growth will continue to decline. The firm warned in its note, &#8220;Unless tariff-related uncertainty is resolved quickly, the path ahead could be towards a sharp, synchronous slowdown.&#8221;
China&#8217;s economic growth in the second quarter is currently projected to fall below 4.5%, a slowdown from the 5.4% expansion recorded in the first quarter, according to Robin Xing, Morgan Stanley&#8217;s chief China economist.
Although China is anticipated to introduce another stimulus package of &nbsp;1-1.5 trillion yuan (nearly $137.5 billion) in the latter half of the year, Morgan Stanley cautions that it will fall short of fully countering the growth shock caused by tariffs.
Meanwhile, Nomura cautioned if China were to lose 50% of its exports to the U.S., it could face a direct GDP reduction of approximately 1.1% in the short term.
SEE ALSO:&nbsp;<a href="https://benzinga.com/25/04/45057119/anthony-scaramucci-bought-1200-worth-of-microsoft-stock-for-his-son-in-1992-and-then-forgot-about-it-three-decade" target="_blank" rel="noreferrer noopener">Anthony Scaramucci Once Purchased $1,200 Worth Of Microsoft Stock For His Son In 1992 And Then Forgot About It — Three Decades Later, It Quietly Turned Into A Small Fortune That He Didn&#8217;t Know He Ow</a>
Why It Matters: To date, Washington has implemented tariffs amounting to 145% on Chinese imports, pushing the overall effective tariff rate to around 156%. In retaliation, Beijing has increased its tariffs on U.S. goods to 125%, adding to earlier duties already in place.
The ongoing tariff war has had significant repercussions on various sectors. For instance,&nbsp;<a href="https://www.benzinga.com/25/04/45059743/china-open-to-co-operate-with-us-firms-voices-concern-over-trade-war-impact-as-tariffs-hits-chinese-airlines-and-boeing">Chinese airlines and Boeing</a>&nbsp;have been adversely affected by U.S.-imposed tariffs. Despite this, there are differing opinions on the potential economic impact. 
CNBC&#8217;s Jim Cramer&nbsp;<a href="https://www.benzinga.com/markets/equities/25/04/45058829/jim-cramer-dismisses-recession-panic-says-tariffs-may-sting-but-too-many-jobs-for-economy-to-derail">dismisses recession fears</a>, arguing that strong employment trends could prevent an economic downturn. However,&nbsp;<a href="https://www.benzinga.com/news/25/04/44913962/donald-trumps-trade-war-jpmorgan-predicts-deals-higher-taxes-and-potential-recession-avoidance">JPMorgan</a>&nbsp;has predicted that the tariff war could lead to agreements between the U.S, and its trade partners, along with a significant rise in tax rates.
Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) declined 7.4%, while the&nbsp;SPDR S&amp;P 500&nbsp;ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) lost 5.78% on a year-to-date basis, amid tariff uncertainties.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/general/sports/25/04/45027895/why-shaq-wont-share-his-500-million-fortune-with-his-kids-we-aint-rich-im-rich-im-not-going-to-hand-it-to-you-you-gotta-earn-it" target="_blank" rel="noreferrer noopener">Why Shaq Won't Share His $500 Million Fortune With His Kids: ‘We Ain't Rich. I'm Rich. I'm Not Going to Hand It to You, You Gotta Earn It&#8217; &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

US, China To Ease Tariffs Gradually After 'Complex' Talks, Says Morgan Stanley — But Cuts China's Growth Outlook

Approximately $1.7 million in product orders are expected to be recognized in fiscal 2026

ALOT

AstroNova Wins $10M Multi-Year Defense Industry Contract

Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Annamycin is potentially a highly versatile drug capable of working synergistically with numerous mechanistically different FDA approved anticancer first line therapies both in vitro and in vivo
HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced that an abstract and poster presentation regarding the Company's next-generation anthracycline, <a href="https://www.globenewswire.com/Tracker?data=zMBqbidS4LQA1S7fbn3PZhXfXzcxSvzhdfQuHUVO-SsFA0PD6bJcUHZORfhgpqRe8EY9wADIXFyqcTM8Qwgz7JLveCs_xMDixJ2BLQBWCpI=">Annamycin</a>, was presented at the <a href="https://www.globenewswire.com/Tracker?data=qQb184I71tqjyRhQ-GjKdptMM-tMvyWkWLtH9kQJaRkS7iRzdL9JHY8KSqkKh_ffpwFkr7X43SoS-zr5uOnoINb9kRqlIWvQvcpWK-kVeaKL7I6vQq-aqXTCoIBKiQx5UVIKi44s0nKo0BpQparUnF5AyJhjHy0qTftsO78LSuK7rn1ih4QQzcSKnNYOn0eiSV_WzgsTpwrOOShzfF4rQg==">American Association for Cancer Research (AACR) Annual Meeting 2025</a>, on April 28, 2025, at the McCormick Place Convention Center in Chicago, IL.

MBRX

Moleculin Presents New Pre-Clinical Data For Annamycin Demonstrating Market Expansion Potential Including Treatment For Pancreatic Cancer At AACR 2025

Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) with a Buy and lowers the price target from $3.5 to $2.5.

BDSX

Canaccord Genuity Maintains Buy on Biodesix, Lowers Price Target to $2.5

Baird analyst Joe Vruwink maintains Cadence Design Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) with a Outperform and raises the price target from $293 to $325.

Comments

Hope Bancorp

Hope Bancorp (HOPE) Opciones

Hope Bancorp (NASDAQ:HOPE) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL